Johnson & Johnson vs. Pfizer: The Future of Healthcare Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy JNJ?
Source: Fool
- Successful Spin-off: Johnson & Johnson's spin-off of its slow-growing consumer health division into Kenvue in 2023 has led to enhanced operational efficiency, with revenue reaching $88.8 billion in 2024 and projected to grow to between $99.5 billion and $100.5 billion by 2026, indicating strong growth potential in the healthcare market.
- Pfizer's Revenue Challenges: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; despite efforts to strengthen its oncology pipeline through acquisitions like Seagen and Metsera, revenue is expected to remain flat in 2026, ranging from $59.5 billion to $62.5 billion, highlighting growth risks.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, while Johnson & Johnson's yield stands at 2.1%; although Pfizer appears undervalued with a lower forward P/E ratio, its lower future earnings expectations may signal risks, whereas Johnson & Johnson's 60+ years of consistent dividend growth suggests greater sustainability.
- Market Outlook Analysis: Amid concerns over inflation, AI bubbles, and geopolitical risks, Johnson & Johnson's broad product portfolio, steady cash flow, and reliable dividend payments position it as a focal point for investors seeking potential shareholder returns over the next decade.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 241.310
Low
190.00
Averages
218.50
High
240.00
Current: 241.310
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strong Growth Amidst Significant Challenges for Johnson & Johnson
- Consistent Revenue Growth: Despite facing challenges such as patent expirations and drug pricing negotiations, Johnson & Johnson is projected to exceed $100 billion in revenue for 2023, demonstrating resilience and a strong market position in a tough environment.
- Significant Patent Risks: Johnson & Johnson lost patent protection for Stelara in 2023, which peaked at $10.9 billion in sales, accounting for nearly 13% of total revenue, posing a potential threat to future earnings.
- Robust Financial Foundation: The company holds an AAA rating from S&P Global, indicating a strong financial position capable of weathering potential lawsuits and market fluctuations, thereby enhancing investor confidence.
- Stable Dividend Policy: With 63 consecutive years of dividend increases, Johnson & Johnson is an ideal choice for investors seeking stable income amid economic uncertainty, further solidifying its leadership in the healthcare sector.
See More
Johnson & Johnson vs. Pfizer: The Future of Healthcare Stocks
- Successful Spin-off: Johnson & Johnson's spin-off of its slow-growing consumer health division into Kenvue in 2023 has led to enhanced operational efficiency, with revenue reaching $88.8 billion in 2024 and projected to grow to between $99.5 billion and $100.5 billion by 2026, indicating strong growth potential in the healthcare market.
- Pfizer's Revenue Challenges: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; despite efforts to strengthen its oncology pipeline through acquisitions like Seagen and Metsera, revenue is expected to remain flat in 2026, ranging from $59.5 billion to $62.5 billion, highlighting growth risks.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, while Johnson & Johnson's yield stands at 2.1%; although Pfizer appears undervalued with a lower forward P/E ratio, its lower future earnings expectations may signal risks, whereas Johnson & Johnson's 60+ years of consistent dividend growth suggests greater sustainability.
- Market Outlook Analysis: Amid concerns over inflation, AI bubbles, and geopolitical risks, Johnson & Johnson's broad product portfolio, steady cash flow, and reliable dividend payments position it as a focal point for investors seeking potential shareholder returns over the next decade.
See More
Market Performance Analysis of Johnson & Johnson and Pfizer
- Johnson & Johnson Revenue Growth: Johnson & Johnson recorded $88.8 billion in revenue for 2024, with projections of $94.2 billion for 2025 and an expected range of $99.5 billion to $100.5 billion for 2026, indicating a clearer business focus and enhanced growth following the spin-off of its consumer health division.
- Pfizer Revenue Decline: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; while its drug development efforts, particularly in oncology and the acquisition of Seagen, suggest future growth potential, the short-term revenue stability remains a concern.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, compared to Johnson & Johnson's 2.1%; although Pfizer's yield appears more attractive, Johnson & Johnson's consistent dividend increases over the past 60 years reflect its financial stability and sustainability.
- Market Outlook Assessment: In the current economic climate, Johnson & Johnson demonstrates higher growth potential due to its diverse product portfolio and steady cash flow, leading analysts to favor its future earnings capability, making it a suitable focus for long-term investors.
See More
Stock Showdown: Johnson & Johnson vs. Pfizer
- Johnson & Johnson Revenue Growth: Johnson & Johnson recorded $88.8 billion in revenue for 2024, with projections of $94.2 billion for 2025 and expected sales between $99.5 billion and $100.5 billion for 2026, indicating enhanced operational efficiency and growth potential following the spin-off of its consumer health division.
- Pfizer Revenue Decline: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; however, the company is actively developing new drugs, particularly bolstering its oncology segment through the acquisition of Seagen, with the global oncology drug market projected to grow from $286 billion in 2026 to $679 billion by 2034.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, while Johnson & Johnson's yield stands at 2.1%; despite Pfizer's lower P/E ratio, concerns about the sustainability of its dividend arise from stagnant revenue growth, whereas Johnson & Johnson's over 60 years of dividend increases suggest greater reliability for investors.
- Market Outlook Analysis: In the current economic climate, Johnson & Johnson demonstrates stronger market competitiveness due to its stable cash flow and increasing revenue, while Pfizer must rely on the success of its drug pipeline to maintain shareholder returns, prompting investors to carefully assess the investment value of each company.
See More
Analyzing Market Volatility and Investment Strategies
- Market Volatility Analysis: In 2026, stock market volatility has intensified, with the S&P 500 typically experiencing an average intra-year drawdown of 14%, highlighting the need for investors to understand this phenomenon to maintain confidence in long-term investments and seize opportunities to buy quality companies during downturns.
- Importance of Diversification: As market uncertainty escalates, diversification can mitigate risks and prevent significant losses from poor performance of a single company, ensuring that investors maintain stable returns across different economic cycles.
- Lessons from History: Investors faced over a 60% drawdown in their portfolios during the 2008-2009 financial crisis; however, by continuing to invest and maintaining a calm mindset, they ultimately achieved significant returns, underscoring the importance of patience and a long-term perspective.
- Future Market Outlook: Despite potential further volatility in 2026, analysts generally believe that the market will rebound in five years, prompting investors to focus on long-term growth potential, particularly in stable sectors like healthcare and consumer goods for investment opportunities.
See More
2026 Market Volatility and Investment Strategies
- Understanding Market Volatility: In 2026, stock market volatility has intensified, with the S&P 500 typically experiencing an average intra-year drawdown of 14%, highlighting the need for investors to grasp this phenomenon to maintain confidence in long-term investments and seize opportunities to buy quality companies during downturns.
- Investor Mindset: Matt Frankel experienced a 60% drop in his portfolio during the 2008 financial crisis, but by continuing to invest and maintaining a calm demeanor, he ultimately achieved a 500% return, underscoring the importance of staying composed during market downturns.
- Importance of Diversification: Rachel Warren emphasizes that excessive concentration in investments can lead to significant losses, while diversification effectively spreads risk, helping investors maintain stable returns amidst market volatility and ensuring long-term growth.
- Sector Performance Disparities: In 2026, tech stocks have underperformed, while consumer goods and healthcare sectors have thrived, with Johnson & Johnson's stock rising 20% year-to-date, demonstrating the investment value of stable industries in uncertain markets.
See More
Strong Growth Amidst Significant Challenges for Johnson & Johnson
- Consistent Revenue Growth: Despite facing challenges such as patent expirations and drug pricing negotiations, Johnson & Johnson is projected to exceed $100 billion in revenue for 2023, demonstrating resilience and a strong market position in a tough environment.
- Significant Patent Risks: Johnson & Johnson lost patent protection for Stelara in 2023, which peaked at $10.9 billion in sales, accounting for nearly 13% of total revenue, posing a potential threat to future earnings.
- Robust Financial Foundation: The company holds an AAA rating from S&P Global, indicating a strong financial position capable of weathering potential lawsuits and market fluctuations, thereby enhancing investor confidence.
- Stable Dividend Policy: With 63 consecutive years of dividend increases, Johnson & Johnson is an ideal choice for investors seeking stable income amid economic uncertainty, further solidifying its leadership in the healthcare sector.
See More
Johnson & Johnson vs. Pfizer: The Future of Healthcare Stocks
- Successful Spin-off: Johnson & Johnson's spin-off of its slow-growing consumer health division into Kenvue in 2023 has led to enhanced operational efficiency, with revenue reaching $88.8 billion in 2024 and projected to grow to between $99.5 billion and $100.5 billion by 2026, indicating strong growth potential in the healthcare market.
- Pfizer's Revenue Challenges: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; despite efforts to strengthen its oncology pipeline through acquisitions like Seagen and Metsera, revenue is expected to remain flat in 2026, ranging from $59.5 billion to $62.5 billion, highlighting growth risks.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, while Johnson & Johnson's yield stands at 2.1%; although Pfizer appears undervalued with a lower forward P/E ratio, its lower future earnings expectations may signal risks, whereas Johnson & Johnson's 60+ years of consistent dividend growth suggests greater sustainability.
- Market Outlook Analysis: Amid concerns over inflation, AI bubbles, and geopolitical risks, Johnson & Johnson's broad product portfolio, steady cash flow, and reliable dividend payments position it as a focal point for investors seeking potential shareholder returns over the next decade.
See More
Market Performance Analysis of Johnson & Johnson and Pfizer
- Johnson & Johnson Revenue Growth: Johnson & Johnson recorded $88.8 billion in revenue for 2024, with projections of $94.2 billion for 2025 and an expected range of $99.5 billion to $100.5 billion for 2026, indicating a clearer business focus and enhanced growth following the spin-off of its consumer health division.
- Pfizer Revenue Decline: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; while its drug development efforts, particularly in oncology and the acquisition of Seagen, suggest future growth potential, the short-term revenue stability remains a concern.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, compared to Johnson & Johnson's 2.1%; although Pfizer's yield appears more attractive, Johnson & Johnson's consistent dividend increases over the past 60 years reflect its financial stability and sustainability.
- Market Outlook Assessment: In the current economic climate, Johnson & Johnson demonstrates higher growth potential due to its diverse product portfolio and steady cash flow, leading analysts to favor its future earnings capability, making it a suitable focus for long-term investors.
See More
Stock Showdown: Johnson & Johnson vs. Pfizer
- Johnson & Johnson Revenue Growth: Johnson & Johnson recorded $88.8 billion in revenue for 2024, with projections of $94.2 billion for 2025 and expected sales between $99.5 billion and $100.5 billion for 2026, indicating enhanced operational efficiency and growth potential following the spin-off of its consumer health division.
- Pfizer Revenue Decline: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; however, the company is actively developing new drugs, particularly bolstering its oncology segment through the acquisition of Seagen, with the global oncology drug market projected to grow from $286 billion in 2026 to $679 billion by 2034.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, while Johnson & Johnson's yield stands at 2.1%; despite Pfizer's lower P/E ratio, concerns about the sustainability of its dividend arise from stagnant revenue growth, whereas Johnson & Johnson's over 60 years of dividend increases suggest greater reliability for investors.
- Market Outlook Analysis: In the current economic climate, Johnson & Johnson demonstrates stronger market competitiveness due to its stable cash flow and increasing revenue, while Pfizer must rely on the success of its drug pipeline to maintain shareholder returns, prompting investors to carefully assess the investment value of each company.
See More
Analyzing Market Volatility and Investment Strategies
- Market Volatility Analysis: In 2026, stock market volatility has intensified, with the S&P 500 typically experiencing an average intra-year drawdown of 14%, highlighting the need for investors to understand this phenomenon to maintain confidence in long-term investments and seize opportunities to buy quality companies during downturns.
- Importance of Diversification: As market uncertainty escalates, diversification can mitigate risks and prevent significant losses from poor performance of a single company, ensuring that investors maintain stable returns across different economic cycles.
- Lessons from History: Investors faced over a 60% drawdown in their portfolios during the 2008-2009 financial crisis; however, by continuing to invest and maintaining a calm mindset, they ultimately achieved significant returns, underscoring the importance of patience and a long-term perspective.
- Future Market Outlook: Despite potential further volatility in 2026, analysts generally believe that the market will rebound in five years, prompting investors to focus on long-term growth potential, particularly in stable sectors like healthcare and consumer goods for investment opportunities.
See More
2026 Market Volatility and Investment Strategies
- Understanding Market Volatility: In 2026, stock market volatility has intensified, with the S&P 500 typically experiencing an average intra-year drawdown of 14%, highlighting the need for investors to grasp this phenomenon to maintain confidence in long-term investments and seize opportunities to buy quality companies during downturns.
- Investor Mindset: Matt Frankel experienced a 60% drop in his portfolio during the 2008 financial crisis, but by continuing to invest and maintaining a calm demeanor, he ultimately achieved a 500% return, underscoring the importance of staying composed during market downturns.
- Importance of Diversification: Rachel Warren emphasizes that excessive concentration in investments can lead to significant losses, while diversification effectively spreads risk, helping investors maintain stable returns amidst market volatility and ensuring long-term growth.
- Sector Performance Disparities: In 2026, tech stocks have underperformed, while consumer goods and healthcare sectors have thrived, with Johnson & Johnson's stock rising 20% year-to-date, demonstrating the investment value of stable industries in uncertain markets.
See More
